Medicilon | Featured Sponsor for ACCESS ASIA BD Forum @ JPM 2026
January 11, 2026 | InterContinental San Francisco In a world where biotech innovation thrives on collaboration, Medicilon as the Featured Sponsor for the ACCESS ASIA BD Forum @ JPM 2026. Our Mission: Your Partner from Concept to IND As a global leader in integrated preclinical research services, Medicilon has long been the bridge between discovery […]
Advancing a New Paradigm in Drug Development: Medicilon and Xellar Biosystems Forge a Strategic Partnership
Shanghai, November 6, 2025 – At the 8th China International Import Expo, Medicilon officially signed a strategic cooperation agreement with Xellar Biosystems, a biotech company pioneering the integration of organ-on-a-chip and AI technologies. This partnership combines Medicilon’s one-stop preclinical drug R&D service platform with Xellar’s advanced organ-on-a-chip systems, AI analytics, and high-content 3D imaging to […]
Medicilon Earns OECD GLP Certification from Hungary, Strengthening Global Compliance Network
Shanghai, China – October 9, 2025 – Medicilon is proud to announce that it has officially obtained certification of compliance with OECD Good Laboratory Practice (GLP) standards from Hungary, a member country of the Organization for Economic Co-operation and Development (OECD). This achievement marks another important milestone in Medicilon’s continuous pursuit of international quality excellence, […]
Medicilon Empowers Strategic Partner SAPU to Obtain Clinical Trial Approval for Sapu003 in Australia
Recently, Sapu003, an innovative drug developed by SAPU Bioscience, has officially obtained clinical trial approval in Australia. This is the first successfully approved IND since Medicilon and SAPU entered into a strategic agreement for 20 IND projects in February this year. The quality and speed of this approval serve as a strong testament to the […]
Medicilon Receives International Accreditation Again! Successfully Obtains OECD GLP Certificate
Recently, Medicilon has officially obtained the Good Laboratory Practice (GLP) certificate issued by Mexico, a member country of the Organization for Economic Co-operation and Development (OECD). Medicilon also has passed the GLP on-site inspections conducted by Hungary, another member country of the OECD. Following the recent FDA and PMDA GLP audit , this success further […]
Medicilon: Innovating Globally at CMC-China Expo 2025
CMC-China Expo 2025 August 1, 2025–The CMC-China Expo 2025, themed “Breakthrough, Symbiosis, and Globalization,” opened today at the Suzhou International Expo Centre. The conference gathers biopharmaceutical experts and executives to foster collaboration on innovative technologies and explore future industry development, addressing key topics to drive high-quality growth in the biopharmaceutical sector. Top 20 Preclinical CROs […]
Novamab Announces NMPA CDE Approval of IND for LQ036, the World’s First Inhaled Nanobody for Moderate-to-Severe Asthma
Novamab has announced that the CDE of the NMPA has approved its IND application for LQ036, the world’s first inhaled nanobody for moderate to severe asthma. LQ036 is a recombinant anti-IL-4Rα single-domain antibody nebulizing solution produced in Pichia pastoris. Medicilon leveraged its dedicated Inhalation Formulation R&D Platform to deliver high quality services for the inhalation […]
China &US Dual Filing Secured! Medicilon Supports Sungening’s SG-1001 in Achieving FDA IND Clearance
June 27, 2025– SG-1001, an antifungal developed by Sungening, has received IND clearance from the U.S. FDA to initiate Phase I clinical trials. It follows its earlier clinical approval in China, making a significant milestone, dual IND clearances in both countries. This milestone not only marks a critical step in Sungening’s global strategy but also […]
Peptide Therapeutics: Preclinical Strategy
The CBA China Annual Conference 2025 successfully concluded in Suzhou on June 28, gathering over 30,000 professionals across 120+ forums to explore technological advancements and global collaboration. Dr. Hanjun Zou, TFM of Medicilon Chuansha, presented “Peptide Therapeutics: Preclinical Strategy,” detailing non-clinical research strategies for peptide drugs to accelerate their development and to improve treatment options. […]
Medicilon Highlights at the 2025 CBA-China Conference
June 28, 2025 –The Chinese Biopharmaceutical Association (CBA-China) Annual Conference concluded successfully in Suzhou, gathering over 1200 leaders from political, industrial, academic, and research sectors to explore technological advancements and global collaboration. Medicilon at CBA-China 2025: Showcasing Innovation & Global Leadership As a leading full-service preclinical R&D CRO, Medicilon actively participated in the CBA-China 2025 […]
